Livforsakringsbolaget Skandia, Omsesidigt Nektar Therapeutics Transaction History

Livforsakringsbolaget Skandia, Omsesidigt

  • $1.72 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 28, 2020
SELL
$15.87 - $23.12 $23,805 - $34,680
-1,500 Closed
0 $0
Q3 2018

Oct 26, 2018
SELL
$46.46 - $68.49 $60,398 - $89,037
-1,300 Reduced 46.43%
1,500 $91,000
Q2 2018

Jul 10, 2018
BUY
$46.25 - $104.45 $129,500 - $292,460
2,800 New
2,800 $137,000

Others Institutions Holding NKTR

# of Institutions
145
Shares Held
139M
Call Options Held
32.6K
Put Options Held
14.1K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email